Hepatocellular carcinoma: Epidemic and treatment

Current Oncology Reports

Volumn 6, Issue 3, 2004, Pages 177-183

  Allen, Jill ^a   Venook, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYCLOOXYGENASE 2 INHIBITOR; IODINATED POPPYSEED OIL; IODINE 131; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE;

ADOPTIVE IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER STAGING; CANCER THERAPY; CATHETER ABLATION; CHEMOEMBOLIZATION; CLINICAL TRIAL; EPIDEMIC; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; PROGNOSIS; REVIEW; SURVIVAL RATE; VACCINATION;

EID: 5444230919     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0047-9     Document Type: Review

References (66)

1. Globocan 2000: Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. Lyon, France: IARC Press; 2001.
2. Centers for Disease Control: Hepatitis B virus: a comprehensive strategy for eliminating transmission in the US through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid Mortal Weekly Rep 1991, 40:RR-13.
3. National Cancer Institute: SEER Cancer Statistics Review 1975-2000. http://www.seer.cancer.gov.
4. Rasi G, Pierimarchi P, Sinibaldi Vallebona P, et al.: Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. HCC. Int Immunopharmacol 2003, 3:1169-1197.
5. Yu MC, Yuan JM, Govindarajan S, Ross RK: Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000, 8: 03-709.
6. Lee W: Hepatitis B infection. N Engl J Med 1997, 337:1733-1745.
7. Maddrey W: Hepatitis B-an important public health issue. Clin Lab 2001, 47:51-55.
8. El Sarag HB: Hepatocellular carcinoma and Hepatitis C in the United States. Hepatology 2002:574-583.
9. Alter MI: Epidemiology of hepatitis C. Hepatology 1997, 26(Suppl 1):62s-65s.
10. Centers for Disease Control. http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm: 2003.
11. Davila JA, Petersena NJ, Nelson HA, El-Serag HB: Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol 2003, 5: 87-493.
12. Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality and costs in the U.S. Am J Public Health 2000, 90:1562-1569.
13. Montalto G, Cervello M, Giannitrapani L, et al.: Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002, 963:13-20.
14. Centers for Disease Control and Prevention: Global progress toward universal childhood hepatitis B vaccination, 2003. Morbid Mortal Weekly Rep 2003, 52:868-870.
15. Bruix J, Llovet J: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35: 19-524.
16. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
17. Llovet JM, Real MI, Montana X, et al.: Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002, 359:1734-1741.
18. Varela M, Sala M, Llovet JM, Bruix J: Natural history and prognostic prediction of patients with HCC. Aliment Pharmacol Ther 2003, 17(Suppl 2):98-102.
19. Cancer of the Liver Italian Program Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998, 28:751-755.
20. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and HCC. The Cancer of the Liver Italian Program Investigators. Hepatology 2000, 31: 79-680.
21. Leung TW, Tang AM, Zee B, et al.: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the CLIP staging system. Cancer 2002, 94:1760-1769.
22. Varela M, Sala M, Llovet JM, Bruix J: Treatment of hepatocellular carcinoma: Is there an optimal strategy? Cancer Treat Rev 2003, 29:99-104.
23. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ: The outcome of liver transplantation in patients with hepatocellular Carcinoma in the United States Between 1988 and 2001: 5-year survival has improved significantly with Time. J Clin Oncol 2003, 21:4329-4335.
24. Sonoyama T, Ochiai T, Hironaka T, Yamagishi H: Predictors of postoperative diffuse intrahepatic recurrence of hepatocellular carcinoma. Hepatogastroenterology 2003, 50:1078-1084.
25. Vauthey JN, Lauwers GY, Esnaola NF, et al.: Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 15:1527-1536.
26. Hemming AW: Liver transplantation for hepatocellular carcinoma. Ann Surg 2001, 233:652-659.
27. Yao F: The Impact of expansion of conventional tumor criteria and pre-operative loco-regional treatments on survival following liver transplantation for hepatocellular carcinoma: results from two centers. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 24-28, 2003; abstract 3.
28. Chao Y, Li CP, Chan GY, et al.: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with respectable HCC after surgery. Ann Surg Oncol 2003, 10:355-362.
29. Baffis V, Shrier I, Sherker AH, Szilagyi A: Use of interferon for prevention of HCC in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999, 31: 96-701.
30. Yao F: Dramatic reduction of the AFP level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J Clin Gastroenterol 2003, 36:440-442.
31. National Cancer Institute: Hepatocellular Cancer (PDQ): Screening. http://www.nci.nih,gov/cancerinfo/pdq. Last updated June 2003.
32. Bruix J, Sherman M, Llovet JM, et al.: Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:42:1-430.
33. Bolondi L, Sofia S, Siringo S, et al.: Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 2001, 48:251-259.
34. Nguyen MH, Keeffe EB: Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002, 35(Suppl 2 ):S86-S91.
35. Mela M, Mancuso A, Burroughs AK: Hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther 2003, 17(Suppl 2):130-137.
36. Yao FY, Bass NM, Nikolai B, et al.: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002, 8:873-883.
37. Kamath PS, Wiesner RH, Malinchoc M, et al.: A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 22:464-470.
38. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
39. Venook AP, Ferrell LD, Roberts JP, et al.: Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg 1995, 1:242-248.
40. Yao FY, Ferrell L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
41. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S: Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000, 89:2266-2273.
42. Yao FY, Ferrell L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002, 8:765-774.
43. Aqel BA, Gores G, Steers J, et al.: Expanding the selection criteria for transplant patients with hepatocellular carcinoma: a world of caution. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 24-28, 2003; abstract 1238.
44. Cavazzoni E, Meehan MD, Shackleton C, et al.: Pre-transplant adjuvant therapy for hepatocellular carcinoma results in a survival disadvantage. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 24-28, 2003; abstract 1241.
45. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
46. Sarasin FP, Majno PE, Llovet JM, et al.: Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001, 33:1073-1079.
47. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
48. Galandi D, Antes G: Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2002, 3:CD003046.
49. GaianiS, Celli N, Cecilioni L, et al.: Percutaneous treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2003, 17(Suppl 2):103-110.
50. Bolondi L, Piscaglia F, Camaggi V, et al.: Liver transplantation for hepatocellular carcinoma: treatment options on the waiting list. Aliment Pharmacol Ther 2003, 17(Suppl 2): 45-150.
51. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000, 356:802-807.
52. Sun H-C: Preventive treatments for recurrence after curative resection of hepatocellular carcinoma: a literature review of randomized control trials. World J Gastroenterol 2003, 9: 35-640.
53. Lau WY, Leung TW, Ho SK, et al.: Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999, 353: 97-801.
54. Muto Y, Moriwaki H, Ninomiya M, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996, 334:1561-1567.
55. Chao Y, Li CP, Chau GY, et al.: Prognostic significance of VEGF, bFGF, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003, 104:355-362.
56. Jia WD, Xu GL, Xu RN, et al.: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003, 129:327-334.
57. Kouroumalis E, Skordilis P, Thermos K, et al.: Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998, 42:442-447.
58. Patt YZ, Hassan MM, Lozano RD, et al.: Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000, 3:319-321.
59. Shiota G, Okubo M, Noumi T, et al.: Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999, 46:407-412.
60. Koga H, Sakisaka S, Ohishi M, et al.: Expression of cyclooxygenase-2 in human hepatocelluar carcinoma: relevance to tumor dedifferentiation. Hepatology 1999, 3:688-696.
61. Bae SH, Jung ES, Park YM, et al.: Expression cyclooxygenase-2 in human hepatocelluar carcinoma and growth inhibition of hepatoma cell lines by a cox-2 inhibitor, NS-398. Clin Cancer Res 2001, 7:1410-1418.
62. Kern MA, Schubert D, Sahi D, et al.: Proapoptotic and anti-proliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36:885-894.
63. Hu KQ, Yu CH, Mineyama Y, et al.: Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol 2003, 4: 57-763.
64. Ito Y, Takeda T, Sakon M, et al.: Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001, 18:1377-1383.
65. Kira S, Nakanishi T, Suemori S, et al.: Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997, 4:177-182.
66. Matsuo M, Sakurai H, Saiki I: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003, 2:557-561.